Upamostat

Drug Profile

Upamostat

Alternative Names: Mesupron; WX-671

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Wilex
  • Developer WILEX AG
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Serine endopeptidase inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Pancreatic cancer
  • Discontinued Head and neck cancer

Most Recent Events

  • 05 Jan 2017 RedHill Biopharma and Aarhus University enter into a research collaboration for evaluation of molecular targets of upamostat
  • 13 Jan 2016 Link Health files an IND application with the China Food and Drug Administration in China for Solid tumours
  • 13 Jan 2016 Link Health plans a phase I trial for Solid tumours in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top